Why Standard BioTools Inc.’s (LAB) Stock Is Down 7.69%
As of Monday, November 16, Standard BioTools Inc.’s LAB share price has dipped by 7.69%, which has investors questioning if this is right time to buy.Tudor Pop
| SECTOR | INDUSTRY |
| Health Care | Life Sciences Tools & Services |
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Jenna Brashear
Tudor Pop
Cynthia McLaughlin
Michael Rose
| Share Statistics | LAB | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $245.2 | $3,632.0 | 31% |
|
| Shares Out (Mil) | 393.6 | 107.2 | 85% |
|
| Institutional Ownership | 92.9% | 89.3% | 62% |
|
| Float (Mil) | 187.8 | 77.0 | 72% |
|
| Beta | 1.51 | 1.15 | 82% |
|
| Avg Daily Volume (000s) | 819 | 1,019 | 65% |
|
| Price Change (52-week) |
(48.3%) | 82.0% | 21% |
|
| Growth | LAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | (9.2%) | 7.5% | 6% |
|
| Net Income (5yr) | (7.2%) | (12.1%) | 32% |
|
| EPS (5yr) | 23.3% | 2.1% | 73 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | (16.9%) | (14.9%) | 42% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | ($0.030) | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | 1 | na | na | |
| # Rev Down | 0 | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | (21.1%) | na | na | |
| Financials | LAB | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $84 | $811 | 24% |
|
| Net Income (TTM) (Mil) | $133 | ($19) | 63% |
|
| EPS (TTM) | $0.342 | ($0.300) | 49% |
|
| Operating Cash Flow (TTM) (Mil) | ($64) | $52 | 8% |
|
| Net Cash Flow (TTM) (Mil) | na | $3 | na |
|
| Long-Term Debt (Q1) (Mil) | $21 | $252 | 33% |
|
| Enterprise Value (Q1) (Mil) | ($155) | $3,486 | 0% |
|
| Valuation | LAB | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.44 | 3.59 | 10% |
|
| P/E | na | 35.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 6.6 | na |
|
| Ratios | LAB | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 52.2% | 47.8% | 64% |
|
| Net Margin | 157.6% | (3.0%) | 100% |
|
| ROA | 22.7% | (5.4%) | 97% |
|
| ROE | 27.9% | (5.2%) | 86% |
|
| Liabilities to Assets | 12.5% | 41.5% | 8% |
|
| F-Score | 5 | 5 | 50% |
|
Standard BioTools Inc. did not pass any screens on 11/16/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors